View:
Download DOC
Download PDF
Download XLS

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2013

 

Commission File Number: 001-34541

 

CHINA CORD BLOOD CORPORATION
(Translation of registrant’s name into English)

 

48th Floor, Bank of China Tower
1 Garden Road
Central
                      Hong Kong S.A.R.                           
(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨ No x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.

 

 
 

EXPLANATORY NOTE

 

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or China Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions; uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date of this Report on Form 6-K, and the Company does not intend to update any of the forward-looking statements after the date of this Report on Form 6-K to confirm these statements to actual results, unless required by law.

 

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; compliance with restrictive debt covenants under the Company’s senior convertible notes; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission.

 

 
 

 

Results of Operations and Financial Condition

 

Following this cover page are the preliminary unaudited condensed consolidated financial results for the three months and nine months ended December 31, 2012 of the Company.

 

 
 

 

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and December 31, 2012

 

 

   March 31,   December 31, 
   2012   2012 
   RMB   RMB   US$ 
   (in thousands except share data) 
             
ASSETS               
Current assets               
Cash and cash equivalents   794,311    1,480,842    237,692 
Accounts receivable, less allowance for doubtful accounts
(March 31, 2012: RMB13,916; December 31, 2012: RMB14,547)		   79,012    77,894    12,502 
Inventories   6,666    7,371    1,183 
Prepaid expenses and other receivables   11,561    13,272    2,130 
Trading securities   354    -    - 
Debt issuance costs   -    3,704    595 
Deferred tax assets   5,268    5,868    942 
Total current assets   897,172    1,588,951    255,044 
Property, plant and equipment, net   267,862    382,216    61,350 
Non-current prepayments   2,863    226,904    36,420 
Non-current accounts receivable, less allowance for doubtful accounts
(March 31, 2012: RMB38,628; December 31, 2012: RMB39,384)		   254,236    248,663    39,913 
Inventories   34,651    38,783    6,225 
Intangible assets, net   129,791    126,326    20,277 
Available-for-sale equity securities   98,199    77,060    12,369 
Other investment   134,363    134,363    21,567 
Debt issuance costs   -    12,663    2,033 
Deferred tax assets   5,013    5,082    816 
Total assets   1,824,150    2,841,011    456,014 
                
LIABILITIES               
Current liabilities               
Bank loan   45,000    50,000    8,026 
Accounts payable   6,343    16,914    2,715 
Accrued expenses and other payables   33,351    79,292    12,728 
Deferred revenue   106,110    147,608    23,693 
Amounts due to related party   360    720    116 
Income tax payable   5,943    8,361    1,342 
Total current liabilities   197,107    302,895    48,620 
Convertible notes   -    748,075    120,074 
Non-current deferred revenue   306,534    474,605    76,179 
Other non-current liabilities   60,420    88,836    14,259 
Deferred tax liabilities   24,462    23,191    3,722 
Total liabilities   588,523    1,637,602    262,854 

 

EQUITY               
Shareholders’ equity               
Ordinary shares               
- US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares               
issued and outstanding as of March 31, 2012 and 73,140,147 shares               
issued and 73,003,248 shares outstanding as of December 31, 2012   50    50    8 
Additional paid-in capital   865,654    798,221    128,123 
Treasury stock, at cost (March 31, 2012: nil; December 31, 2012: 136,899 shares)   -    (2,815)   (452)
Accumulated other comprehensive income   26,057    3,297    529 
Retained earnings   310,973    400,392    64,268 
Total shareholders’ equity   1,202,734    1,199,145    192,476 
Non-controlling interests   32,893    4,264    684 
Total equity   1,235,627    1,203,409    193,160 
Total liabilities and equity   1,824,150    2,841,011    456,014 

 

 
 

 

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Nine Months ended December 31, 2011 and 2012

  

   Three months ended December 31,   Nine months ended December 31, 
   2011   2012   2011   2012 
   RMB   RMB   US$   RMB   RMB   US$ 
   (in thousands except share data) 
                         
Revenues   94,821    149,320    23,967    280,712    393,112    63,099 
Direct costs   (21,703)   (28,268)   (4,537)   (63,328)   (79,714)   (12,795)
Gross profit   73,118    121,052    19,430    217,384    313,398    50,304 
Operating expenses                              
Research and development   (1,953)   (2,087)   (335)   (5,662)   (6,210)   (997)
Sales and marketing   (16,930)   (24,831)   (3,986)   (45,111)   (67,568)   (10,845)
General and administrative   (22,711)   (27,009)   (4,335)   (66,610)   (81,053)   (13,009)
Total operating expenses   (41,594)   (53,927)   (8,656)   (117,383)   (154,831)   (24,851)
Operating income   31,524    67,125    10,774    100,001    158,567    25,453 
Other income/(expense), net                              
Interest income   3,570    3,874    622    10,021    11,062    1,776 
Interest expense   (741)   (23,762)   (3,814)   (2,391)   (48,027)   (7,709)
Exchange gain/(loss)   3,484    (1,010)   (162)   (1,376)   (959)   (154)
Dividend income   -    2,265    364    7,217    4,685    752 
Others   (411)   45    7    (86)   (721)   (116)
Total other income/(expense), net   5,902    (18,588)   (2,983)   13,385    (33,960)   (5,451)
Income before income tax   37,426    48,537    7,791    113,386    124,607    20,002 
Income tax credit/(expense)   4,273    (13,259)   (2,128)   (3,037)   (28,060)   (4,504)
Net income   41,699    35,278    5,663    110,349    96,547    15,498 
Net income attributable to non-controlling interests   (2,229)   (1,647)   (264)   (7,608)   (7,128)   (1,144)
Net income attributable to the Company   39,470    33,631    5,399    102,741    89,419    14,354 
                               
Net income per share:                              
Attributable to ordinary shares                              
- Basic   0.54    0.42    0.07    1.39    1.17    0.19 
- Diluted   0.54    0.42    0.07    1.39    1.17    0.19 
                               
Other comprehensive income                              
- Net effect of foreign currency translation, net of nil tax   (360)   784    126    (1,049)   (1,640)   (263)
- Net unrealized gain/(loss) in available-for-sale equity securities, net of nil tax   40    (1,193)   (191)   (11,468)   (21,143)   (3,394)
Comprehensive income   41,379    34,869    5,598    97,832    73,764    11,841 
                               
Comprehensive income attributable to non-controlling interests   (2,250)   (1,646)   (264)   (7,855)   (7,105)   (1,140)
Comprehensive income attributable to the Company   39,129    33,223    5,334    89,977    66,659    10,701 
 
 

 

Other Events

 

On February 26, 2013, the Company issued a press release announcing preliminary unaudited condensed consolidated financial results for the three months and nine months ended December 31, 2012. A copy of the press release is attached as Exhibit 99.1.

 

Exhibits

 

  Exhibit No.   Description
       
  99.1   Press Release, dated February 26, 2013

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CHINA CORD BLOOD CORPORATION
     
  By: /s/ Albert Chen
  Name: Albert Chen
  Title: Chief Financial Officer

 

Dated: February 26, 2013 

 

 

 

 

China Cord Blood Corporation Reports Financial Results

for the Third Quarter and First Nine Months of Fiscal 2013

 

3Q13 New Subscribers Up 65.0% YOY to 21,218

3Q13 Revenue Up 57.5% YOY to RMB149.3 Million

3Q13 Operating Income Up 112.9% YOY to RMB67.1 Million

Conference Call to be Held February 27, 2013 at 8:00 a.m. ET

 

HONG KONG, China, February 26, 2013 — China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the third quarter and first nine months of fiscal year 2013, which ended December 31, 2012.

 

Third Quarter of Fiscal 2013 Highlights

 

·Revenues for the third quarter of fiscal 2013 increased by 57.5% to RMB149.3 million ($24.0 million) from RMB94.8 million in the prior year period.
·New subscriber sign-ups increased 65.0% year-over-year to 21,218.
·Accumulated subscriber base amounted to 295,923.
·Gross profit increased by 65.6% to RMB121.1 million ($19.4 million) from RMB73.1 million in the prior year period.
·Gross margin was 81.1%, an increase from 77.1% in the prior year period.
·Operating income increased by 112.9% to RMB67.1 million ($10.8 million) from RMB31.5 million in the prior year period.
·Interest expense amounted to RMB23.8 million ($3.8 million), compared to RMB0.7 million in the prior year period.
·Income before income tax for the third quarter grew by a lesser extent of 29.7% because of higher interest expense and lack of exchange gain.
·Net income attributable to the Company was RMB33.6 million ($5.4 million), a decrease of 14.8% compared to the same period last year also due to higher interest expense and lack of exchange gain and a one-time tax benefit recorded in the third quarter of fiscal 2012.
·Operating cash inflow for the quarter amounted to RMB144.1 million ($23.1 million).

 

First Nine Months of Fiscal 2013 Highlights

 

·Revenues for the first nine months of fiscal 2013 increased by 40.0% to RMB393.1 million ($63.1 million) from RMB280.7 million in the prior year period.
·New subscriber sign-ups reached 56,169 and the accumulated subscriber base expanded to 295,923.
·Gross profit increased by 44.2% to RMB313.4 million ($50.3 million) from RMB217.4 million in the prior year period.
·Operating income increased by 58.6% to RMB158.6 million ($25.5 million) from RMB100.0 million in the prior year period.
·Interest expense amounted to RMB48.0 million ($7.7 million), compared to RMB2.4 million in the prior year period.
·Income before income tax was RMB124.6 million ($20.0 million), up 9.9%.
·In the absence of the one-time tax benefit, net income attributable to the Company amounted to RMB89.4 million ($14.4 million), compared to RMB102.7 million in the prior year period.
·Operating cash inflow for the first nine months of fiscal 2013 was RMB423.6 million ($68.0 million).

 

 
 

 

 

“The Company reached a major milestone in the third quarter of fiscal 2013 as we, for the first time, exceeded the 20,000 mark in quarterly new subscriber numbers, representing the highest increase in our new subscriber sign-ups in any single quarter, and generated record quarterly revenues,” stated Ms. Ting Zheng, Chief Executive Officer of CCBC. “Such achievements reflect our management team’s years of dedication to setting out clear strategies and marketing approaches to optimize our marketing campaign, payment methods, and client base. Our robust financial performance reflects the harvest of our continuous efforts to deepen penetration in our existing markets, which leads to ongoing expansion in our subscriber base, as well as increasingly high earnings and cash flows. By continuously revamping our marketing approach, we have been able to achieve our short-to-medium term objectives in today’s dynamics business environment.”

 

Summary – The Third Quarter and First Nine Months Ended December 31, 2011 and 2012

 

   Three Months Ended December 31,   Nine Months Ended December 31, 
   2011   2012   2011   2012 
(in thousands)  RMB   RMB   US$   RMB   RMB   US$ 
Revenues   94,821    149,320    23,967    280,712    393,112    63,099 
Gross Profit   73,118    121,052    19,430    217,384    313,398    50,304 
Operating Income   31,524    67,125    10,774    100,001    158,567    25,453 
Net Income Attributable to the Company   39,470    33,631    5,399    102,741    89,419    14,354 
Earnings per Ordinary Shares
– Basic1 and Diluted (RMB/US$)		   0.54    0.42    0.07    1.39    1.17    0.19 
                               
Revenue Breakdown (%)                              
Processing Fees   72.9%   77.4%        74.0%   76.5%     
Storage Fees   27.1%   22.6%        26.0%   23.5%     
                               
New Subscribers (persons)   12,861    21,218         39,588    56,169      
Total Accumulated Subscribers (persons)   225,418    295,923         225,418    295,923      

 

Summary – Selected Cash Flow Statement Items

 

   Three Months Ended   Nine Months Ended 
   December 31, 2012   December 31, 2012 
(in thousands)  RMB   US$   RMB   US$ 
Net cash provided by operating activities   144,147    23,137    423,553    67,985 
Net cash used in investing activities   (267,996)   (43,016)   (356,420)   (57,209)
Net cash provided by financing activities   281,108    45,121    621,468    99,752 

  

 

1 The terms of the convertible notes issued to KKR and Golden Meditech provide KKR and Golden Meditech with the ability to participate in any excess cash dividend. Therefore, the calculation of basic EPS has taken into consideration of such participating rights effect of RMB0.05 ($0.01) and RMB0.08 ($0.01) for the three months and nine months ended December 31, 2012, respectively.

 

 
 

 

 

Third Quarter Fiscal 2013 Financial Results

 

REVENUES. Revenues increased by 57.5% to RMB149.3 million ($24.0 million) in the third quarter of fiscal 2013 from RMB94.8 million in the prior year period, driven by the significant increase in new subscriber sign-ups during the quarter and ongoing expansion in the accumulated subscriber base which now totals nearly 300,000.

 

Revenues generated from storage fees increased to RMB33.8 million ($5.4 million), up 31.5% from RMB25.7 million in the prior year period. As a result of the large increase in new subscriber numbers, contributing revenue from storage fees proportionally declined to account for approximately 22.6% of total revenues, compared to 27.1% in the prior year period.

 

Revenues generated from processing fees were RMB115.5 million ($18.6 million), up 67.1% from RMB69.1 million in the prior year period, reflecting a record 21,218 new subscriber sign-ups this quarter, representing a 65.0% year-over-year increase and a 14.7% quarter-over-quarter increase. Revenues generated from processing fees accounted for 77.4% of total revenues, compared to 72.9% in the prior year period.

 

GROSS PROFIT. Gross profit for the third quarter of fiscal 2013 increased by 65.6% to RMB121.1 million ($19.4 million) from RMB73.1 million in the prior year period, benefiting from economies of scale and better cost control, which helped to offset rising direct costs. Gross margin expanded to 81.1%, compared to 77.1% in the prior year period.

 

OPERATING INCOME. Operating income for the third quarter increased 112.9% to RMB67.1 million ($10.8 million) compared to RMB31.5 million in the prior year period. Operating margin also rose to 45.0%, compared to 33.2% in the prior year period, as a result of increased revenue and higher efficiencies associated with economies of scale. Depreciation and amortization expenses for the third quarter were RMB8.4 million ($1.3 million), compared to RMB7.4 million in the prior year period.

 

Research and Development Expenses. Research and development expenses remained stable at RMB2.1 million ($0.3 million) compared to RMB2.0 million in the prior year period, as a reflection of the Company’s continuous efforts to enhance operations through technology advancement.

 

Sales and Marketing Expenses. Sales and marketing expenses increased by 46.7% to RMB24.8 million ($4.0 million) from RMB16.9 million in the prior year period. This was driven by the Company’s continuous investment in marketing across the Beijing, Guangdong and Zhejiang markets and efforts to educate more people about the benefits of cord blood banking services. During the period, sales and marketing expenses were managed to maintain a level of approximately 16.6% of revenues in the third quarter of fiscal 2013, down from 17.9% in the prior year period.

 

General and Administrative Expenses. General and administrative expenses were RMB27.0 million ($4.3 million), compared to RMB22.7 million in the prior year period, mainly due to an increase in staff-related costs and transaction costs related to the recent corporate restructuring. The increase in general administrative expenses is consistent with management expectations.

 

OTHER INCOME AND EXPENSES

 

Interest Expense. Interest expense increased to RMB23.8 million ($3.8 million) from RMB0.7 million in the prior year period. The increase was largely attributable to the convertible notes issued to KKR China Healthcare Investment Limited (“KKR”) and Golden Meditech Holdings Limited (“Golden Meditech”). In the third quarter of fiscal 2013, interest expense related to the convertible notes annual coupon interest payment amounted to RMB12.7 million ($2.0 million) and the amortization of other related costs amounted to RMB10.0 million ($1.6 million).

 

 
 

 

 

NET INCOME ATTRIBUTABLE TO THE COMPANY. Income before income tax for the third quarter grew by a lesser extent of 29.7% because of the higher interest expense and the lack of exchange gain recorded in the comparable prior third quarter. The Company recorded an exchange gain of RMB3.5 million during the third quarter of fiscal 2012 versus an exchange loss of RMB1.0 million ($0.2 million) during the third quarter of fiscal 2013, but the impact was partially offset by the dividend income of RMB2.3 million ($0.4 million) contributed by Cordlife Group Limited recorded in the current quarter. For the third quarter of fiscal 2012, the Company recorded a one-time tax benefit from the preferential tax treatment for our subsidiaries. There was no such tax benefit recorded for third quarter of fiscal 2013. As a result, net income attributable to the Company for the third quarter of fiscal 2013 amounted to RMB33.6 million ($5.4 million), decreased by 14.8% from RMB39.5 million in the prior year period. Net margin for the third quarter of fiscal 2013 was 22.5%.

 

EARNINGS PER SHARE. The terms of the convertible notes issued to KKR and Golden Meditech provide KKR and Golden Meditech with the ability to participate in any Excess Cash Dividend.2 Therefore, the calculation of basic and diluted EPS has taken into consideration of such participating rights effect of RMB0.05 ($0.01). Basic and diluted earnings per ordinary share for the third quarter of fiscal 2013 were RMB0.42 ($0.07).

 

LIQUIDITY. As of December 31, 2012, the Company had cash and cash equivalents of RMB1,480.8 million ($237.7 million) compared to RMB794.3 million as of March 31, 2012. The Company had total debt of RMB798.1 million ($128.1 million) as of December 31, 2012. Operating cash inflow for the quarter amounted to RMB144.1 million ($23.1 million).

 

First Nine Months Fiscal 2013 Financial Results

 

For the first nine months of fiscal year 2013, total revenues increased by 40.0% to RMB393.1 million ($63.1 million) from RMB280.7 million in the prior year period. The increase was largely attributable to the significant increase in new subscribers and the expansion of the Company’s accumulated subscriber base to 295,923 subscribers. Processing fees and storage fees grew by 44.7% and 26.7%, respectively. Gross profit increased by 44.2% to RMB313.4 million ($50.3 million) from RMB217.4 million in the prior year period. Operating income increased by 58.6% to RMB158.6 million ($25.5 million) from RMB100.0 million in the prior year period. Interest expense increased to RMB48.0 million ($7.7 million) from RMB2.4 million in the prior year period. The increase was largely attributable to the convertible notes issuance. Income before income tax grew 9.9% to RMB124.6 million ($20.0 million), from RMB113.4 million in the prior year period. In light of the absence of the one-time tax benefit recorded during the nine months ended December 31, 2012, net income attributable to the Company decreased to RMB89.4 million ($14.4 million). Basic and diluted earnings per share attributable to ordinary shares were RMB1.17 ($0.19). Net cash provided by operating activities in the first nine months of fiscal 2013 was RMB423.6 million ($68.0 million).

 

“The significant cash flow generated by the increase in new subscriber numbers will enable CCBC to move forward with our expansion plans through both organic growth in our existing markets and seeking new strategic acquisition opportunities,” Ms. Zheng further commented. “Our full equity ownership in our Guangdong subsidiary and increased equity interest in Shandong Cord Blood Blank are evidence of our progress towards increasing our market positioning throughout affluent and high-growth potential regions of China. These achievements not only reflect our commitment to expand our footprint in China, but also testify to management’s abilities of reaching our goals step-by-step.”

 

 

2 “Excess Cash Dividend” means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% in such financial year divided by the number of shares into which the note is convertible at the conversion price then in effect on the relevant record date.

 

 
 

 

 

Ms. Zheng concluded, “We believe that there is much untapped market potential in all the markets we serve, and we are now in the process of expanding our Guangdong facility to meet further demand in this market. With the continuous efforts to widen market exposure through effective marketing tools in order to realize the huge potential within in our existing markets, we are encouraged by the consistently rising market demand from both the Beijing and Guangdong markets, as well as being excited to see positive response in the start-up phase of our Zhejiang operation. We are pleased with the achievements that we have made and excited by the vast opportunities ahead of us. We will strive to achieve our medium- to long-term corporate objectives by continuously refining our marketing strategies, quality standards, and operational strategy, and in turn, maximizing corporate value and return to our shareholders.”

 

Conference Call

 

The Company will host a conference call at 8:00 a.m. ET on Wednesday, February 27, 2013 to discuss its financial performance and give a brief overview of the Company’s recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company’s IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 90798569.

 

About China Cord Blood Corporation

 

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

 

Safe Harbor Statement

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions; uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date of this press release, and the Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results, unless required by law.

 

 
 

 

 

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in China, as well as general economic conditions; compliance with restrictive debt covenants under our senior convertible notes; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

 

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending December 31, 2012 were made at the noon buying rate of RMB6.2301 to $1.00 on December 31, 2012 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

 

For more information, please contact:

 

China Cord Blood Corporation

Investor Relations Department

Tel: (+852) 3605-8180

Email: [email protected]

 

ICR, Inc.

Mr. Rob Koepp

Tel: (+86) 10-6583-7516

U.S. Tel: (646) 405-5185

Email: [email protected]

 

 
 

 

 

EXHIBIT 1

CHINA CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
As of March 31 and December 31, 2012

 

   March 31,   December 31, 
   2012   2012 
   RMB   RMB   US$ 
   (in thousands except share data) 
             
ASSETS               
Current assets               
Cash and cash equivalents   794,311    1,480,842    237,692 
Accounts receivable, less allowance for doubtful accounts
(March 31, 2012: RMB13,916; December 31, 2012: RMB14,547)		   79,012    77,894    12,502 
Inventories   6,666    7,371    1,183 
Prepaid expenses and other receivables   11,561    13,272    2,130 
Trading securities   354    -    - 
Debt issuance costs   -    3,704    595 
Deferred tax assets   5,268    5,868    942 
Total current assets   897,172    1,588,951    255,044 
Property, plant and equipment, net   267,862    382,216    61,350 
Non-current prepayments   2,863    226,904    36,420 
Non-current accounts receivable, less allowance for doubtful accounts
(March 31, 2012: RMB38,628; December 31, 2012: RMB39,384)		   254,236    248,663    39,913 
Inventories   34,651    38,783    6,225 
Intangible assets, net   129,791    126,326    20,277 
Available-for-sale equity securities   98,199    77,060    12,369 
Other investment   134,363    134,363    21,567 
Debt issuance costs   -    12,663    2,033 
Deferred tax assets   5,013    5,082    816 
Total assets   1,824,150    2,841,011    456,014 
                
LIABILITIES               
Current liabilities               
Bank loan   45,000    50,000    8,026 
Accounts payable   6,343    16,914    2,715 
Accrued expenses and other payables   33,351    79,292    12,728 
Deferred revenue   106,110    147,608    23,693 
Amounts due to related party   360    720    116 
Income tax payable   5,943    8,361    1,342 
Total current liabilities   197,107    302,895    48,620 
Convertible notes   -    748,075    120,074 
Non-current deferred revenue   306,534    474,605    76,179 
Other non-current liabilities   60,420    88,836    14,259 
Deferred tax liabilities   24,462    23,191    3,722 
Total liabilities   588,523    1,637,602    262,854 

 

EQUITY               
Shareholders’ equity               
Ordinary shares               
- US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued and outstanding as of March 31, 2012 and 73,140,147 shares issued and 73,003,248 shares outstanding as of December 31, 2012   50    50    8 
Additional paid-in capital   865,654    798,221    128,123 
Treasury stock, at cost (March 31, 2012: nil; December 31, 2012: 136,899 shares)   -    (2,815)   (452)
Accumulated other comprehensive income   26,057    3,297    529 
Retained earnings   310,973    400,392    64,268 
Total shareholders’ equity   1,202,734    1,199,145    192,476 
Non-controlling interests   32,893    4,264    684 
Total equity   1,235,627    1,203,409    193,160 
Total liabilities and equity   1,824,150    2,841,011    456,014 

 

 
 

 

 

EXHIBIT 2

 

CHINA CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the Three Months and Nine Months ended December 31, 2011 and 2012

 

   Three months ended December 31,   Nine months ended December 31, 
   2011   2012   2011   2012 
   RMB   RMB   US$   RMB   RMB   US$ 
   (in thousands except share data) 
                         
Revenues   94,821    149,320    23,967    280,712    393,112    63,099 
Direct costs   (21,703)   (28,268)   (4,537)   (63,328)   (79,714)   (12,795)
Gross profit   73,118    121,052    19,430    217,384    313,398    50,304 
Operating expenses                              
Research and development   (1,953)   (2,087)   (335)   (5,662)   (6,210)   (997)
Sales and marketing   (16,930)   (24,831)   (3,986)   (45,111)   (67,568)   (10,845)
General and administrative   (22,711)   (27,009)   (4,335)   (66,610)   (81,053)   (13,009)
Total operating expenses   (41,594)   (53,927)   (8,656)   (117,383)   (154,831)   (24,851)
Operating income   31,524    67,125    10,774    100,001    158,567    25,453 
Other income/(expense), net                              
Interest income   3,570    3,874    622    10,021    11,062    1,776 
Interest expense   (741)   (23,762)   (3,814)   (2,391)   (48,027)   (7,709)
Exchange gain/(loss)   3,484    (1,010)   (162)   (1,376)   (959)   (154)
Dividend income   -    2,265    364    7,217    4,685    752 
Others   (411)   45    7    (86)   (721)   (116)
Total other income/(expense), net   5,902    (18,588)   (2,983)   13,385    (33,960)   (5,451)
Income before income tax   37,426    48,537    7,791    113,386    124,607    20,002 
Income tax credit/(expense)   4,273    (13,259)   (2,128)   (3,037)   (28,060)   (4,504)
Net income   41,699    35,278    5,663    110,349    96,547    15,498 
Net income attributable to non-controlling interests   (2,229)   (1,647)   (264)   (7,608)   (7,128)   (1,144)
Net income attributable to the Company   39,470    33,631    5,399    102,741    89,419    14,354 
                               
Net income per share:                              
Attributable to ordinary shares                              
- Basic   0.54    0.42    0.07    1.39    1.17    0.19 
- Diluted   0.54    0.42    0.07    1.39    1.17    0.19 
                              

Other comprehensive income                              
- Net effect of foreign currency translation, net of nil tax   (360)   784    126    (1,049)   (1,640)   (263)
- Net unrealized gain/(loss) in available-for-sale equity securities, net of nil tax   40    (1,193)   (191)   (11,468)   (21,143)   (3,394)
Comprehensive income   41,379    34,869    5,598    97,832    73,764    11,841 
                               
Comprehensive income attributable to non-controlling interests   (2,250)   (1,646)   (264)   (7,855)   (7,105)   (1,140)
Comprehensive income attributable to the Company   39,129    33,223    5,334    89,977    66,659    10,701